Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis

Basit Öğe Kaydı
dc.contributor.authorGümüş Güler B.
dc.contributor.authorÖzler S.
dc.date.accessioned2020-03-26T20:20:50Z
dc.date.available2020-03-26T20:20:50Z
dc.date.issued2020
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA). Methods: This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). The primary end points were the perinatal outcome and the response to UDCA therapy. A logistic regression model was used to identify the independent risk factors of adverse pregnancy outcomes and reduced response to UDCA therapy. Results: Women with ICP had significantly higher serum syndecan-1 (1.27 ± 0.36 ng/mL vs. 0.98 ± 0.50 ng/mL; P = 0.003), glypican-3 (1.78 ± 0.13 ng/mL vs.1.69 ± 0.16 ng/mL; P = 0.004), AST (128.59 ± 1.44 vs. 13.29 ± 1.32 U/L; P < 0.001), and ALT (129.84 ± 1.53 vs. 8.00 ± 3.67 U/L; P < 0.001) levels compared with the controls. The increased levels of syndecan-1 (OR = 4.715, 95% CI: 1.554–14.310; P = 0.006), glypican-3 (OR = 8.465, 95% CI: 3.372–21.248; P = 0.007), ALT (OR = 1.382, 95% CI: 1.131–1.690; P = 0.002), and postprandial bile acid (PBA) (OR = 3.392, 95% CI: 1.003–12.869; P = 0.026) were correlated to ICP. The adverse neonatal outcome was related to increased glypican-3 (OR = 4.275, 95% CI: 2.726–5.635; P = 0.039), and PBA (OR = 3.026, 95% CI: 1.069–13.569; P = 0.037). Increases of syndecan-1 (OR = 7.464, 95% CI: 2.130–26.153, P = 0.017) and glypican-3 (OR = 6.194, 95% CI: 2.951–13.002; P = 0.025) were the risk factors of decreased response to UDCA treatment. Conclusion: Syndecan-1 and glypican-3 might be powerful determinants in predicting adverse perinatal outcome in patients with ICP, and they can be used to predict the response to the UDCA treatment. © 2020 First Affiliated Hospital, Zhejiang University School of Medicine in Chinaen_US
dc.description.sponsorshipNone. This study was approved by the Ethics Committee of the Liv Hospital Affiliated to University of ?stinye, Turkey (2018-003/015). No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.en_US
dc.identifier.doi10.1016/j.hbpd.2019.12.001en_US
dc.identifier.issn1499-3872en_US
dc.identifier.pmid31919038en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.hbpd.2019.12.001
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38680
dc.identifier.wosWOS:000541381600010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier (Singapore) Pte Ltden_US
dc.relation.ispartofHepatobiliary and Pancreatic Diseases Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdverse perinatal outcomeen_US
dc.subjectGlypican-3en_US
dc.subjectIntrahepatic cholestasis of pregnancyen_US
dc.subjectResponse to UDCAen_US
dc.subjectSyndecan-1en_US
dc.titleIncreased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu